Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Beats on EPS, Stock Up 1.87%

Catalyst Pharmaceuticals reported a narrower-than-expected loss per share, which led to a positive stock reaction, rising 1.87%. However, there was no revenue reported or guidance provided, leaving investors with limited insight into future performance. The EPS surprise indicates some level of operational efficiency, but the lack of revenue data raises questions about overall growth.